Market Currents
SA author The GeoTeam argues that SciClone (SCLN) faces risks that should see it trade at...
-
Wednesday, July 11, 2012, 9:48 AM ETSA author The GeoTeam argues that SciClone (SCLN) faces risks that should see it trade at $2.65-$3.80. These include: the failure of the firm's Zadaxin drug, its lead product, in multiple Phase III studies for various uses; probable price reductions in China, SciClone's main source of revenue; and an SEC investigation into bribery in the country. Shares -5.4% to $6.50.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
